Use of Formula Fortified With DHA in Infants With Cystic Fibrosis

NACompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Cystic Fibrosis
Interventions
DIETARY_SUPPLEMENT

Docosahexaenoic acid (DHA)

Infant formula with 0.96% of fatty acids as DHA

DIETARY_SUPPLEMENT

Standard formula (Enfamil)

This is a standard, commercially available infant formula.

Trial Locations (24)

10595

Children's Hospital at Westchester Medical Center, Valhalla

11040

Schneider Children's Hospital, New Hyde Park

11794

Univesity Medical Center, Stony Brook

12208

Albany Medical Center, Albany

13210

SUNY Upstate Medical Center, Syracuse

14222

Children's Hospital, Buffalo

14642

Strong Memorial Hospital, Rochester

15231

Children's Hospital of Pittsburgh, Pittsburgh

19134

St. Christopher's Hospital for Children, Philadelphia

26506

Mountain State University, Morgantown

30322

Emory Cystic Fibrosis Center, Atlanta

35233

UAB/CHS Cystic Fibrosis Center, Birmingham

40202

Kosair Charities, Louisville

44308

Lewis H Walker CF Pulmonary Center, Akron

Lewis H Walker Cystic Fibrosis Center Division of Pulmonary, Akron

50309

Blank Children's Hospital, Des Moines

64108

Children's Mercy Hospital, Kansas City

67218

Cystic Fibrosis Care & Teaching Center, Wichita

02114

Massachusetts General Hospital, Boston

02115

Children's Hospital, Boston

01199

Baystate Medical Center, Springfield

01655

UMass Memorial Healthcare, Worcester

07740

Monmouth Medical Center, Long Branch

07962-1956

The Respiratory Center for Children, Morristown

All Listed Sponsors
collaborator

Cystic Fibrosis Foundation

OTHER

lead

University of Massachusetts, Worcester

OTHER

NCT00530244 - Use of Formula Fortified With DHA in Infants With Cystic Fibrosis | Biotech Hunter | Biotech Hunter